Jing-Jing Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing-Jing Yang has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Hui Tao
Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University , Hefei , 230601
25 shared publications Li-Chan Lin
Department of Cardiothoracic Surgery, Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, People's Republic of China
17 shared publicationsZhi-Yan Liu
Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, PR China; Center for Scientific Research and Experiment, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, PR China
14 shared publications- Jian-Yuan Zhao
Institute for Developmental and Regenerative Cardiovascular Medicine, MOE-Shanghai Key Laboratory of Children’s Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200092
12 shared publications Zhen-Yu Liu
Department of Cardiothoracic Surgery, Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, People's Republic of China
10 shared publicationsBin Tu
Department of Cardiothoracic Surgery, Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, People's Republic of China
9 shared publications
Latest Publications
- 25 June 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 252
Extracellular matrix stiffness in chronic liver disease: From mechanisms to treatments
- 25 June 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 252
Extracellular matrix stiffness in chronic liver disease: From mechanisms to treatments
- Open Access
- 3 March 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
SLC31A1 exon 1 methylation reduces intracellular copper ion and promotes diabetic cardiac fibrosis
Metal homeostasis is linked to cellular organelles modification. Dynamic lipid droplet (LD)-mitochondria interactions contribute to diabetes-related complications. However, little is known about whether and how copper regulates LD-mitochondria contacts in diabetic cardiac fibrosis (CF). Leptin receptor-deficient (db/db) mice were used to induce diabetic CF. To investigate target gene function in vivo, AAV9 vectors carrying the cardiac fibroblast-specific POSTN promoter-driven small hairpin RNAs were administered. SLC31A1 overexpression was achieved via AAV9 plasmid specifically targeting cardiac fibroblasts to assess its rescue effect on diabetic CF. In vitro, neonatal mouse primary cardiac fibroblasts were stimulated with high glucose/high fatty acids (HG/HF) to mimic diabetic CF. Lower copper concentrations were accompanied by SLC31A1 downregulation and increased LD-mitochondria contacts in diabetic CF and HG/HF-induced cardiac fibroblasts. Fibroblast-specific SLC31A1 deficiency enhanced the LD-mitochondria contacts, fibroblast proliferation, and diabetic CF. Mechanistically, intracellular copper deficiency inhibited the specific binding of H3K27me3 to the PLIN5 promoter and promoted transcription. Furthermore, enhanced DNMT3A expression increases the DNA methylation level in the exon 1 region of SLC31A1. Increased methylated CpGs recruited MeCP2, suppressing SLC31A1 expression. Conversely, epigenetic repression rescued SLC31A1 expression, resulting in a certain degree of inhibition of diabetic CF. Human diabetic cardiomyopathy (DCM) heart tissue analyses validated our findings. This study demonstrates the critical role of SLC31A1 exon 1 methylation-mediated copper depletion in promoting diabetic CF, identifying cardiac fibroblast-specific rescue of copper depletion as a potential therapeutic approach for diabetic CF. The online version contains supplementary material available at 10.1186/s12933-026-03124-0.
- 3 March 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Open AccessSLC31A1 exon 1 methylation reduces intracellular copper ion and promotes diabetic cardiac fibrosis
Metal homeostasis is linked to cellular organelles modification. Dynamic lipid droplet (LD)-mitochondria interactions contribute to diabetes-related complications. However, little is known about whether and how copper regulates LD-mitochondria contacts in diabetic cardiac fibrosis (CF). Leptin receptor-deficient (db/db) mice were used to induce diabetic CF. To investigate target gene function in vivo, AAV9 vectors carrying the cardiac fibroblast-specific POSTN promoter-driven small hairpin RNAs were administered. SLC31A1 overexpression was achieved via AAV9 plasmid specifically targeting cardiac fibroblasts to assess its rescue effect on diabetic CF. In vitro, neonatal mouse primary cardiac fibroblasts were stimulated with high glucose/high fatty acids (HG/HF) to mimic diabetic CF. Lower copper concentrations were accompanied by SLC31A1 downregulation and increased LD-mitochondria contacts in diabetic CF and HG/HF-induced cardiac fibroblasts. Fibroblast-specific SLC31A1 deficiency enhanced the LD-mitochondria contacts, fibroblast proliferation, and diabetic CF. Mechanistically, intracellular copper deficiency inhibited the specific binding of H3K27me3 to the PLIN5 promoter and promoted transcription. Furthermore, enhanced DNMT3A expression increases the DNA methylation level in the exon 1 region of SLC31A1. Increased methylated CpGs recruited MeCP2, suppressing SLC31A1 expression. Conversely, epigenetic repression rescued SLC31A1 expression, resulting in a certain degree of inhibition of diabetic CF. Human diabetic cardiomyopathy (DCM) heart tissue analyses validated our findings. This study demonstrates the critical role of SLC31A1 exon 1 methylation-mediated copper depletion in promoting diabetic CF, identifying cardiac fibroblast-specific rescue of copper depletion as a potential therapeutic approach for diabetic CF. The online version contains supplementary material available at 10.1186/s12933-026-03124-0.
- Open Access
- 19 January 2026
- Published by Elsevier in Pharmacological Research
- Vol. 224, 108102
Reply to letter to the editor questions and comments on “ALKBH5 attenuates mitochondrial fission and ameliorates liver fibrosis by reducing Drp1 methylation”
- 19 January 2026
- Published by Elsevier in Pharmacological Research
- Vol. 224, 108102
Open AccessReply to letter to the editor questions and comments on “ALKBH5 attenuates mitochondrial fission and ameliorates liver fibrosis by reducing Drp1 methylation”
- 11 September 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 2) , 117325
Epigenetic regulation of extracellular matrix mechanotransduction in cardiac fibrosis
- 11 September 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 2) , 117325
Epigenetic regulation of extracellular matrix mechanotransduction in cardiac fibrosis
- 2 September 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 30 (10) , 104464
Shining light on liquid–liquid phase separation in chronic liver disease
- 2 September 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 30 (10) , 104464
Shining light on liquid–liquid phase separation in chronic liver disease
- 15 July 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 30 (8) , 104429
Dynamic chromatin accessibility landscape changes in cardiac fibrosis
- 15 July 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 30 (8) , 104429
Dynamic chromatin accessibility landscape changes in cardiac fibrosis
- 2 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177888
Novel landscapes of N6-methyladenosine modification of mitochondrial oxidative stress in organ fibrosis
- 2 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177888
Novel landscapes of N6-methyladenosine modification of mitochondrial oxidative stress in organ fibrosis
- Open Access
- 18 June 2025
- Published by Elsevier in Pharmacological Research
- Vol. 218, 107825
Novel insights on post-translational modifications of nucleic acid methylation proteins in hepatic fibrosis
- 18 June 2025
- Published by Elsevier in Pharmacological Research
- Vol. 218, 107825
Open AccessNovel insights on post-translational modifications of nucleic acid methylation proteins in hepatic fibrosis
- 25 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177344
Novel epitranscriptomic and epigenetic therapeutic strategies and targets for ferroptosis in liver fibrosis
- 25 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177344
Novel epitranscriptomic and epigenetic therapeutic strategies and targets for ferroptosis in liver fibrosis
- 2 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 228, 163-172
Targeted mitochondrial function for cardiac fibrosis: An epigenetic perspective
- 2 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 228, 163-172
Targeted mitochondrial function for cardiac fibrosis: An epigenetic perspective